Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy

Programmed death-ligand 1 (PD-L1) expression in tumor tissue is under investigation as a candidate biomarker in immuno-oncology dug development. The soluble form of PD-L1 (sPDL1) is suggested to have immunosuppressive activity. In this study, we measured the serum level of sPDL1 and evaluated its pr...

Full description

Saved in:

Bibliographic Details
Published in:	Oncotarget Vol. 7; no. 47; pp. 76604 - 76612
Main Authors:	Ha, Hyerim, Nam, Ah-Rong, Bang, Ju-Hee, Park, Ji-Eun, Kim, Tae-Yong, Lee, Kyung-Hun, Han, Sae-Won, Im, Seock-Ah, Kim, Tae-You, Bang, Yung-Jue, Oh, Do-Youn
Format:	Journal Article
Language:	English
Published:	United States 22.11.2016
Subjects:	Adult Aged B7-H1 Antigen - blood Bile Duct Neoplasms - blood Bile Duct Neoplasms - diagnosis Bile Duct Neoplasms - drug therapy Bile Duct Neoplasms - mortality Biomarkers Chemotherapy, Adjuvant Female Humans Leukocyte Count Lymphocytes Male Middle Aged Neoplasm Staging Neutrophils Palliative Care Prognosis Treatment Outcome biliary tract cancer PDL1 biomarker soluble PDL1 immunotherapy
ISSN:	1949-2553
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!